Shandong Aishi Biotechnology
Ordered peptides from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.
Test my supplyShandong Aishi Biotechnology's purity-focus record is broad but uneven, with GHK-Cu and Ipamorelin testing strongest while Tirzepatide and Retatrutide show recent purity setbacks. Tesamorelin and HGH sit at the weak end; recent testing is abundant, but batch-ID gaps and fill swings keep the catalog dispersed.
Corporate records tie Aishi to a real Dezhou entity, but registry data and storefront claims conflict over staff, licences and factory capacity. The report maps a dead canonical domain, replacement sales funnels, shared COAs and a near-name buyer-confusion risk.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Shandong Aishi Biotechnology rows.
Cancel anytime
Ordered peptides from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.
Test my supply| Date | Result | Test | Lab | Purity | Dosage | Label | COA |
|---|---|---|---|---|---|---|---|
5 Nov 2026 | Fail | Tirzepatide Shandong Aishi Biotechnology | lab name | View COA | |||
23 Oct 2026 | Pass | Tirzepatide Shandong Aishi Biotechnology | lab name | View COA | |||
5 Oct 2026 | Fail | Tesamorelin Shandong Aishi Biotechnology | lab name | View COA | |||
5 Oct 2026 | Fail | Retatrutide Shandong Aishi Biotechnology | lab name | View COA | |||
24 Sep 2026 | Pass | GHK-Cu Shandong Aishi Biotechnology | lab name | View COA | |||
23 Sep 2026 | Pass | GHK-Cu Shandong Aishi Biotechnology | lab name | View COA | |||
23 Sep 2026 | Fail | Retatrutide Shandong Aishi Biotechnology | lab name | View COA | |||
14 Sep 2026 | Pass | Tirzepatide Shandong Aishi Biotechnology | lab name | View COA | |||
9 Sep 2026 | Pass | GHK-Cu Shandong Aishi Biotechnology | lab name | View COA | |||
26 Aug 2026 | Pass | Tirzepatide Shandong Aishi Biotechnology | lab name | View COA | |||
About Shandong Aishi Biotechnology test results from Finnrick
Shandong Aishi Biotechnology is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 7 peptides and 91 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Shandong Aishi Biotechnology peptides in this dataset are BPC-157 (3 tests), GHK-Cu (16 tests) and HGH (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 91 recent tests.
Ordered peptides from Shandong Aishi Biotechnology? Mail in a sample (US only) and let us test it.
Test my supply